SLC22A17 and myeloproliferative neoplasm: In particular, NGALR expression was shown to be modified in myeloproliferative neoplasm (MPN), colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), glioma, clear cell renal cell carcinoma (ccRCC), glomerulonephritis, hepatocellular carcinoma (HCC), alcoholic hepatitis, obesity, psoriasis, gastric cancer, endometrial cancer, and many other disorders (Table 3).